Gland Pharma Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹1,425Cr
- −7.3% YoY
- +3% QoQ
- Net profit
- ₹187Cr
- −2.6% YoY
- −8.8% QoQ
- Margin
- 24%
- +1 pp YoY
- −2 pp QoQ
Guidance rank: #65 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Gland Pharma Ltd Q4 FY25 key numbers
- Revenue
- Key US growth drivers FY'26: improvement in Cenexi numbers, new product launches, tech transfer projects, dry powder contracts (~Rs 60-70 crores), biologics (~Rs 100 crores).
As stated in Gland Pharma Ltd's Q4 FY25 earnings call transcript · published 5 Aug 2026. Reported figures, not investment advice.
The short version
FY'25 US volume growth: +9%, price decline: -5%; new launches contributed 6% to US revenue with a 72% gross margin. FY'26 overall growth guidance: mid-teens percentage (15%-17%), driven by US business growth, new launches, tech transfer projects, dry powder contracts, and biologics segment (~Rs 100 crores revenue expected in FY'26).
From Gland Pharma Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY'25 US volume growth: +9%, price decline: -5%; new launches contributed 6% to US revenue with a 72% gross margin.
- Consolidated growth guidance for next year (FY'26): mid-teen percentage growth (~15%).
- Key US growth drivers FY'26: improvement in Cenexi numbers, new product launches, tech transfer projects, dry powder contracts (~Rs 60-70 crores), biologics (~Rs 100 crores).
- US volume growth notable in top products (24% volume increase in top 10 products).
- GLP cartridge fill-and-finish market expected to expand significantly; capacity to increase to 140 million cartridges next year from 40 million.
- ROW business expected to double over next 3-5 years via product registrations and cost efficiencies.
- Cenexi to break even by December quarter, aiming for double-digit EBITDA margin in FY'27.
2 more points from Gland Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Gland Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Investment of about INR 120 crores planned for a new cartridge line, expected to be installed by the end of this year.
- A ~60 million euro CAPEX over the next 2-3 years in Cenexi to increase capability and capacity, including:
- Adding a new pre-filled syringe line at Hérouville site for better realization per unit.
- Adding an additional vial line and lyophilization capacity in the Belgium site to boost high-value business.
- Focus on replacing inefficient lines and adding new capacities for lyophilized (Lyo) products to meet growing demand.
- Capacity expansion driven by supply constraints at two sites unable to cater to demand, particularly for Lyo products.
2 more points from Gland Pharma Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Gland Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Cenexi's current order book is around Euro 100 million (Page 22).
- Cenexi has capacity constraints at two sites due to inefficient lines, leading to aggressive capacity expansion (Pages 20-21).
- The company is investing in new and more efficient lines to meet demand, particularly for lyophilized products (Page 21).
- For GLP (glucagon-like peptide) fill and finish, 40 million cartridges capacity is mostly booked; the second line will be operational by year-end to cater to additional partnerships (Pages 22-23).
2 more points from Gland Pharma Ltd's call on order book
Create a free account to keep reading this call
Gland Pharma Ltd — Quarterly revenue & net profit
Gland Pharma Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,425 | 1,537 | -7.3% | 1,384 | +3% |
| Operating profit (EBITDA) | 348 | 359 | -3.1% | 360 | -3.3% |
| Operating margin | 24% | 23% | +1 pp | 26% | -2 pp |
| Profit before tax | 288 | 298 | -3.4% | 299 | -3.7% |
| Net profit (PAT) | 187 | 192 | -2.6% | 205 | -8.8% |
| EPS (₹) | 11.32 | 11.68 | -3.1% | 12.42 | -8.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.8K Cr, net profit ₹291 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gland Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Gland Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gland Pharma Ltd Q4 FY25 results?
FY'25 US volume growth: +9%, price decline: -5%; new launches contributed 6% to US revenue with a 72% gross margin. FY'26 overall growth guidance: mid-teens percentage (15%-17%), driven by US business growth, new launches, tech transfer projects, dry powder contracts, and biologics segment (~Rs 100 crores revenue expected in FY'26).
What is Gland Pharma Ltd share price analysis?
Gland Pharma Ltd currently shows a neutral. The stock trades at a P/E of 42.8 with a market cap of ₹48,998 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gland Pharma Ltd planning capital expenditure?
Investment of about INR 120 crores planned for a new cartridge line, expected to be installed by the end of this year.
Keep Gland Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
